| Candi L Anderson, CNM | |
|
200 1st St Sw, Rochester, MN 55905 | |
| (507) 284-2511 | |
| Not Available |
| Full Name | Candi L Anderson |
|---|---|
| Gender | Female |
| Speciality | Advanced Practice Midwife |
| Location | 200 1st St Sw, Rochester, Minnesota |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013926336 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367A00000X | Advanced Practice Midwife | R157294-8 (Minnesota) | Secondary |
| 367A00000X | Advanced Practice Midwife | 74 (Minnesota) | Primary |
| Entity Name | Mayo Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922074434 PECOS PAC ID: 6507778255 Enrollment ID: O20031103000285 |
News Archive
Sanofi-aventis and its wholly-owned subsidiary, BiPar Sciences, today announced that The New England Journal of Medicine published the final phase II data for the investigational drug iniparib demonstrating significant clinical benefit in women with metastatic triple negative breast cancer when iniparib was administered in combination with chemotherapy agents gemcitabine/carboplatin.
Marking a major milestone in what has become a fast-growing standard of care in prostate cancer surgery, the chief of urologic oncology at The Cancer Institute of New Jersey has completed his 1,000th robotic prostatectomy at Robert Wood Johnson University Hospital (RWJUH), the Flagship Hospital of The Cancer Institute of New Jersey, which is a Center of Excellence of the University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School.
Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that preclinical data in neuroblastoma for perifosine, the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase pathway, will be presented at the 101st Annual Meeting of the American Association for Cancer Research, currently being held at the Walter E. Washington Convention Center in Washington, DC.
University of Pennsylvania, in Philadelphia, PA has installed a MILabs U-SPECT+ system to advance several ongoing research topics. The U-SPECT+ delivers ultra-high resolution, sensitivity, and scanning speed yielding quantification results for brain, cardiac, cancer and musculoskeletal applications.
The presence of collagen in the tumor microenvironment, essentially where the tumor lives, can be either good or bad according to Constance Brinckerhoff, PhD who led the Dartmouth team's reporting of "The BRAFV600E inhibitor, PLX4032, increases type 1 collagen synthesis in melanoma cells," in Matrix Biology Journal.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Candi L Anderson, CNM 200 1st St Sw, Rochester, MN 55905-0001 Ph: (507) 284-2511 | Candi L Anderson, CNM 200 1st St Sw, Rochester, MN 55905 Ph: (507) 284-2511 |
News Archive
Sanofi-aventis and its wholly-owned subsidiary, BiPar Sciences, today announced that The New England Journal of Medicine published the final phase II data for the investigational drug iniparib demonstrating significant clinical benefit in women with metastatic triple negative breast cancer when iniparib was administered in combination with chemotherapy agents gemcitabine/carboplatin.
Marking a major milestone in what has become a fast-growing standard of care in prostate cancer surgery, the chief of urologic oncology at The Cancer Institute of New Jersey has completed his 1,000th robotic prostatectomy at Robert Wood Johnson University Hospital (RWJUH), the Flagship Hospital of The Cancer Institute of New Jersey, which is a Center of Excellence of the University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School.
Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that preclinical data in neuroblastoma for perifosine, the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase pathway, will be presented at the 101st Annual Meeting of the American Association for Cancer Research, currently being held at the Walter E. Washington Convention Center in Washington, DC.
University of Pennsylvania, in Philadelphia, PA has installed a MILabs U-SPECT+ system to advance several ongoing research topics. The U-SPECT+ delivers ultra-high resolution, sensitivity, and scanning speed yielding quantification results for brain, cardiac, cancer and musculoskeletal applications.
The presence of collagen in the tumor microenvironment, essentially where the tumor lives, can be either good or bad according to Constance Brinckerhoff, PhD who led the Dartmouth team's reporting of "The BRAFV600E inhibitor, PLX4032, increases type 1 collagen synthesis in melanoma cells," in Matrix Biology Journal.
› Verified 4 days ago
Mary M Murry, RN Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Sarah K Monson, APRN, CNM Advanced Practice Midwife Medicare: Accepting Medicare Assignments Practice Location: 1650 4th St Se, Rochester, MN 55904 Phone: 507-529-6600 | |
Anna Calhoun, CNM Advanced Practice Midwife Medicare: Medicare Enrolled Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Andrea Lynn Engdahl, APRN, CNM Advanced Practice Midwife Medicare: Accepting Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Rebecca Mary Smith, CNM Advanced Practice Midwife Medicare: Medicare Enrolled Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Michelle M Dynes, RN Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 |